Matthew W. Emmens

2009

In 2009, Matthew W. Emmens earned a total compensation of $19.3M as Chair, President CEO at Vertex Pharmaceuticals.

Compensation breakdown

Non-Equity Incentive Plan$2,846,251
Option Awards$10,699,406
Salary$1,002,693
Stock Awards$4,498,687
Other$231,121
Total$19,278,158

Emmens received $10.7M in option awards, accounting for 55.50% of the total pay in 2009.

Emmens also received $2.8M in non-equity incentive plan, $1M in salary, $4.5M in stock awards and $231.1K in other compensation.

Rankings

In 2009, Matthew W. Emmens' compensation ranked 51st out of 9,538 executives tracked by ExecPay. In other words, Emmens earned more than 99.5% of executives.

ClassificationRankingPercentile
All
51
out of 9,538
100th
Division
Manufacturing
16
out of 3,603
100th
Major group
Chemicals And Allied Products
8
out of 822
99th
Industry group
Drugs
8
out of 607
99th
Industry
Pharmaceutical Preparations
8
out of 427
98th
Source: SEC filing on April 10, 2012.

Emmens' colleagues

We found six more compensation records of executives who worked with Matthew W. Emmens at Vertex Pharmaceuticals in 2009.

2009

Nancy Wysenski

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2009

Joshua Boger

Vertex Pharmaceuticals

Chief Executive Officer

2009

Peter Mueller

Vertex Pharmaceuticals

Chief Scientific Officer

2009

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2009

Amit Sachdev

Vertex Pharmaceuticals

Senior Vice President, Corporate Affairs and Public Policy, and Commercial Business Lead, Canada

2009

Kenneth Boger

Vertex Pharmaceuticals

Chief Legal Officer

In-depth

You may also like